Home > Compound List > Compound details
940310-85-0 molecular structure
click picture or here to close

4-methyl-3-{[1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino}-N-[3-(trifluoromethyl)phenyl]benzamide

ChemBase ID: 72895
Molecular Formular: C26H20F3N7O
Molecular Mass: 503.4785096
Monoisotopic Mass: 503.16814296
SMILES and InChIs

SMILES:
c12c(nc(nc1Nc1cc(ccc1C)C(=O)Nc1cccc(c1)C(F)(F)F)c1cccnc1)n(nc2)C
Canonical SMILES:
Cc1ccc(cc1Nc1nc(nc2c1cnn2C)c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F
InChI:
InChI=1S/C26H20F3N7O/c1-15-8-9-16(25(37)32-19-7-3-6-18(12-19)26(27,28)29)11-21(15)33-23-20-14-31-36(2)24(20)35-22(34-23)17-5-4-10-30-13-17/h3-14H,1-2H3,(H,32,37)(H,33,34,35)
InChIKey:
ZCCPLJOKGAACRT-UHFFFAOYSA-N

Cite this record

CBID:72895 http://www.chembase.cn/molecule-72895.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
4-methyl-3-{[1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino}-N-[3-(trifluoromethyl)phenyl]benzamide
IUPAC Traditional name
4-methyl-3-{[1-methyl-6-(pyridin-3-yl)pyrazolo[3,4-d]pyrimidin-4-yl]amino}-N-[3-(trifluoromethyl)phenyl]benzamide
Synonyms
NVP-BHG712
CAS Number
940310-85-0
PubChem SID
162037815
PubChem CID
16747388

DATA SOURCES

DATA SOURCES

All Sources Commercial Sources Non-commercial Sources
Data Source Data ID Price
Selleck Chemicals
S2202 external link Add to cart Please log in.
Data Source Data ID
PubChem 16747388 external link

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem
Acid pKa 11.55222  H Acceptors
H Donor LogD (pH = 5.5) 5.2930703 
LogD (pH = 7.4) 5.319515  Log P 5.3198924 
Molar Refractivity 156.5083 cm3 Polarizability 49.408146 Å3
Polar Surface Area 97.62 Å2 Rotatable Bonds
Lipinski's Rule of Five false 

PROPERTIES

PROPERTIES

Safety Information Pharmacology Properties Product Information Bioassay(PubChem)
Storage Condition
-20°C expand Show data source
Target
B-Raf expand Show data source
c-Abl expand Show data source
SRC expand Show data source
VEGFR expand Show data source
Salt Data
Free Base expand Show data source

DETAILS

DETAILS

Selleck Chemicals Selleck Chemicals
Selleck Chemicals - S2202 external link
Research Area
Description Cancer
Biological Activity
Description NVP-BHG712 is a specific inhibitor of c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
Targets c-Raf c-Src c-Abl
IC50 0.395 μM 1.266 μM 1.667 μM [1]
In Vitro NVP-BHG712 treatment also dose dependently leads to the inhibition of RTK autophosphorylation in stable transfected A375 melanoma cells with EC50 of 25 nM and 4.2 μM for EphB4 and VEGFR2, respectively. [1]
In Vivo In a growth factor-induced angiogenesis model, NVP-BHG712 (3 mg/kg, p.o) significantly suppresses VEGF stimulated tissue formation and vascularization by inhibiting EphB4 forward signaling. Furthermore, NVP-BHG712 (10 mg/kg/kg, p.o.) potently reverses VEGF enhanced tissue formation and vessel growth. NVP-BHG712 (3 mg/kg, p.o.) shows a long lasting exposure with concentrations around 10 μM in plasma as well as in lung and liver tissue for up to 8 hours, and thus results in a long lasting inhibition of EphB4 kinase activity in mice. [1]
Clinical Trials
Features Discriminates between VEGFR and EphB4
Protocol
Kinase Assay [1]
In vitro kinase assays All in vitro kinase assays are performed with recombinant purified kinases either purchased from external vendors or produced in house. To estimate kinase activity both, TR-FRET-based LanthaScreenTM and Caliper mobility shift are used. In brief, the LanthaScreenTM assay technology is based on the discrimination between the unphosphorylated substrate and the phosphorylated product by a phospho-specific antibody, binding only to the phosphorylated version of the substrate. Both, antibody and substrate, carry fluorescent labels and the close proximity of the labels in the formed complex allows the measurement of a fluorescence resonance energy transfer (FRET) signal. Reading of the FRET signal in a time-dependent/time-gated manner further improves the assay performance by reducing background fluorescence. For dose–response measurements NVP-BHG712 is pre-diluted in 90% DMSO and 50 nL of compound solutions are dispensed directly into the empty assay plate using a HummingBird nanodispenser. The kinase reactions are started by addition of 4.5 μL ATP solution (4 μM ATP, 20 mM Tris/HCL, 1 mM DTT, 0.03% Tween20, 0.01 mM Na3VO4) and 4.5 μL enzyme/substrate mix (100 nM fluorescein poly-GAT), 0.5% bovine serum albumin, 20 mM Tris/HCL, 1 mM DTT, 0.03% Tween20, 0.01 mM Na3VO4). Further components of the enzyme/substrate mix are the enzymes as well as MgCl2/MnCl2 which are adjusted specifically to the requirements of the individual enzyme. After incubation for 60 minutes at r.t. the kinase reactions are stopped by addition of 4.5 μL stop solution (50 mM EDTA pH 8.0, 0.04% NP-40, 20 mM Tris/HCl pH 7.4) followed by 4.5 μL of detection mix (1.72 μg/mL Tb-PY20 antibody), 1% bovine serum albumin, 20 mM Tris/HCl, 1 mM DTT, 0.03% Tween20, 0.01 mM Na3VO4). After incubation for 45 minutes at r.t. plates are analyzed in a BMG PHERAstar plate reader. In the Caliper mobility shift assays kinase reactions are analyzed by microfluidic capillary electrophoresis. The transfer of phosphate from ATP to a short peptide by a kinase causes a change in the net-charge of the peptide by ?2. The charge difference between the unphosphorylated and phosphorylated entities of the peptide can be separated in an electrical field. Using peptides attached with a fluorescent label allows detection and quantification of both forms and hence the calculation of the reaction turnover. For dose–response measurements NVP-BHG712 is pre-diluted in 90% DMSO and 50 nL aliquots of solution are dispensed directly into the empty assay plate using a HummingBird nanodispenser. The kinase reactions are started by addition of 4.5 μL substrate mix consisting of ATP and peptide substrate in assay buffer (50 mM HEPES pH 7.5, 0.02% bovine serum albumin, 1 mM DTT, 0.02% Tween20, 0.01 mM Na34, 10 mM beta-glycerophosphate) and 4.5 μL enzyme solution in assay buffer. The peptide concentration is 2 μM in the assays. Concentrations for the enzyme, as well as for MgCl2 and MnCl2 are adjusted specifically to the requirements of the individual enzyme. ATP concentrations are adjusted to the Km values of the specific enzyme. After incubation for 60 minutes at 30 °C the kinase reactions are stopped by addition of 16 μL stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% coating reagent 10 mM EDTA pH 8.0, 0.015% BRIJ35). Stopped kinase reactions are analyzed in a LC3000 reader.
Animal Study [1]
Animal Models VEGF-mediated angiogenesis in vivo is induced in a growth factor implant model in mice.
Formulation NVP-BHG712 is dissolved in 1-Methyl-2-pyrrolidone (NMP) and then diluted with polyethylene glycol 300 (PEG300) to a final concentration of 10% v/v NMP and 90% v/v PEG300.
Doses ≤30 mg/kg
Administration Administered via p.o.
References
[1] Martiny-Baron G, et al. Angiogenesis. 2010, 13(3), 259-267.

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle